ORIGINAL RESEARCH PAPER

Medical Science

THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE

KEY WORDS: Psychedelics, LSD, MDMA, Depression, Anxiety

Dr Chirag Ambaliya Senior Resident, Department of Psychiatry. Government medical college, Bhavnagar

Dr Dimple Gupta* Senior Resident, Department of Psychiatry. Hamdard Institute of medical sciences and research*Corresponding Author

Dr Ashok U Vala Professor & Head, Department of Psychiatry. Government Medical College, Bhavnagar

Dr Krupa Unadkat Senior Resident, Department of Psychiatry. Government medical college, Bhavnagar

ABSTRACT

The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and MDMA, in the treatment of various mental health conditions, such as depression, anxiety, PTSD, and substance use disorders. This review's main goal is to highlight recent human studies on the use of particular psychedelic drugs, like psilocybin, LSD, MDMA, and ayahuasca, in the treatment of various psychiatric illnesses, such as treatment-resistant depression, post-traumatic stress disorder, end-of-life anxiety, and substance use disorders. There will also be a discussion of the safety and effectiveness as reported from both human and animal studies. Research has shown that psychedelics have the potential to become ground-breaking treatments for mental health disorders that are resistant to traditional therapies.

1.Introduction

The definition of "psychedelic" according to the Oxford Dictionary is to make manifest or reveal the mind, soul, or spirit. The discovery of lysergic acid diethylamide (LSD) by renowned scientist Albert Hoffman in 1943 while investigating alkaloids from the rye ergot fungus is credited with starting the history of psychedelics. It's interesting to note that the same chemist discovered psilocybin in 1958, another hallucinogenic substance. LSD and psilocybin were extensively provided to specialists in the domains of neurology and psychiatry for basic investigative and therapeutic study by Sandoz under the trade names Delysid and Indocybin, respectively. This prompted a quarter-century of enthusiastic psychedelic study at a time when psychopharmacology was rapidly advancing and drugs like chlorpromazine and imipramine were first discovered and produced. (1)

The psycholytic and psychedelic models of treatment were the subjects of early psychedelic research. The psycholytic paradigm focuses on using psychedelics as an adjuvant to enhance psychoanalytic therapy by dispensing tiny dosages over several sessions. Disorders like personality disorders, anxiety, and somatization disorders were all treated with it. On the other hand, the psychedelic model makes use of higher dosages of psychedelic substances that are provided over the course of one or a few sessions in order to produce a "mystical," "peak," or "psychedelic" experience. This approach seeks to elicit long-lasting adjustments to ingrained thought and behaviour patterns. This approach was primarily investigated in people with drug use disorders and has no equivalent in contemporary psychiatric practice. (2)

Many eminent behavioural science leaders hailed these agents as a ground-breaking treatment for intractable psychiatric disorders, such as anxiety in terminal cancer patients, because of their potency and clinically favourable profile. (3)

For instance, throughout the 1950s and 1960s, hundreds of publications on psychedelic research were published globally; it was estimated that over 5000 human subjects in the United Kingdom got LSD in more than 40,000 LSD sessions during that time. (4) However, the promise of psychedelics for therapy and treatment in the 1960s quickly turned sour as their widespread use on the black market in unrestricted settings, frequently by people with serious premorbid psychiatric conditions, led to illicit manufacturing and distribution. The safety of these drugs has been seriously questioned in the wake of reports of "bad trips" marked by hallucinations, intense anxiety to the point of panic, violence, and depression with suicidal thoughts. The rare but frequently widely reported homicide cases following "LSD experiences" further enraged the people. (3,5)

The Substances Act of 1970 in the US was ultimately passed as a result of strong societal and political outcry. The Drug Enforcement Administration (DEA) classified LSD, psilocybin, and several other psychedelic drugs as being under Schedule I, the strictest drug classification. (6)

This designation put an abrupt end to human psychedelic research, and it became nearly impossible to obtain any government financing for new initiatives.

However, some well-known scientists and even politicians, including Dr. Albert Hoffman and Senator Robert Kennedy, continued to strongly support psychedelic medications. In a few labs, rigorous research fusing modern molecular biology with neuroimaging methods started up again in the 1980s. The Multidisciplinary Association for Psychedelic Studies (MAPS), the Heffter Research Institute, and the Beckley Foundation are just a few of the non-profit organisations that have grown in the last ten years to support psychedelic research. These organisations are all supported by private donors and non-governmental organisations. (7)

Modern psychedelic studies are meticulously planned and subjected to stringent approval processes by Institutional Review Boards, in contrast to clinical experiments undertaken in the 1960s, which were frequently uncontrolled and unblinded with uneven methodologies. According to proponents of psychedelic research, the DEA's Schedule I categorization was made on political grounds rather than on the basis of sound science. For instance, past studies have not consistently shown that 5-HT2A agonists, which include

traditional psychedelic drugs like LSD, psilocybin, and mescaline, regularly cause tolerance, withdrawal, and compulsive drug-seeking behaviours similar to those caused by substances with a recognised history of addiction like cocaine and heroin.(8,9)

In fact, as will be discussed below, some of these medications might even have anti-addictive qualities. Second, despite being a Schedule I substance, marijuana has been used successfully in medical contexts and is currently legal in a number of states.(10)

The administration of psychedelic drugs does carry some unique psychological risks (overwhelming distress during drug reaction) as well as brief physiological risks (transient elevation in blood pressure and heart rate). However, these risks can typically be effectively reduced with close medical supervision.(11)

In light of this possible promise for mental treatment, proponents contend that these chemicals merit more funding for scientific research.

The possible mental benefits of psychedelic substances will be the main topic of this review. Today, the term "psychedelics" refers to a variety of drugs that cause a complex clinical syndrome that may alter various cognitive and emotional functions. Although there is no universally agreed-upon definition, "classic psychedelics" and "entactogens" are two general categories for psychedelic substances. The traditional psychedelics are mescaline, DMT, psilocybin, LSD, and psilocybin. All of these medications have agonist pharmacological actions at the 5-HT2A receptor. Among the entactogens is methylenedioxymethamphetamine (MDMA), a serotonin, dopamine, and noradrenaline agonist with a very different mode of action from the traditional psychedelics.(12)

Numerous recent studies have discovered promising clinical benefits of psychedelic drugs for a variety of mental illnesses, including post-traumatic stress disorder (PTSD), depression that is resistant to treatment, anxiety about the end of life, and substance use disorders. Current research suggests that these psychedelic drugs may play a role in altering neuronal transcription, inducing entropic brain activities, and activating cellular pathways distinct from those activated by conventional psychotropic medications, although the pharmacodynamic and neurological underpinnings of how they exert their therapeutic effects are still unknown.(13)

One study specifically demonstrated that tryptamines (DMT, psilocybin), amphetamines (MDMA), and ergolines (LSD), which are representative of all three classes of psychedelics, were able to promote neurite growth in vitro and in fruit fly (Drosophila) larvae; additional experiments further demonstrated mTOR (mammalian target of rapamycin) as a possible downstream mediator for the positive neurotropic effect [67]. Interestingly, despite the difference in target (NMDA versus 5-HT2A), mTOR has also been proposed to be a critical downstream mediator for ketamine. Psilocybin and LSD administration may be associated with decreased amygdala activity, which may help to explain the euphoric effects these drugs frequently have on mood.(14)

It should be noted that ketamine, scopolamine, and ibogaine are occasionally categorised as psychedelic substances. They won't be covered in this review, though. This review will instead concentrate on the most recent developments and prospective applications of a few traditional psychedelics (psilocybin, LSD, and DMT) and MDMA. Each drug's effectiveness and safety in the treatment of psychiatric diseases will be highlighted in significant recent research from the psychiatric literature.(12,13)

2. Psilocybin for Depression and Anxiety:

2.1 Overview of psilocybin and its history in research:

The term "magic mushrooms" or "shrooms" refers to psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), a plant alkaloid linked to tryptamine that is present in a variety of Psilocybe species of mushrooms. Psilocin (4-hydroxy-N,N-dimethyl-tryptamine), which shares structural similarities with serotonin or 5-hydroxytryptamine, is produced right away after consumption. It is regarded as a "classic psychedelic" since it primarily affects the 5-HT2A receptor. It may cause a brief altered state of consciousness in people, which is uncommon to encounter outside of dreams and religious ecstasy and is characterised by pronounced perceptual distortions, affective instability, and mental dysfunction. Psilocybin is currently a Schedule I drug, as was already mentioned. However, numerous recent studies conducted on both healthy volunteers and particular patient populations have shown generally good tolerability and few negative effects. Psilocybin is the main hallucinogenic substance present in some species of mushrooms, also known as "magic mushrooms." These mushrooms have been used for religious and therapeutic purposes by numerous indigenous tribes for ages. In the 1950s and 1960s, modern research on psilocybin started, but its potential therapeutic uses were overshadowed by its connection to the counterculture movement and its designation as a Schedule I substance. Research on psilocybin has recently attracted renewed interest as more people are becoming aware of its possible therapeutic benefits for depression and anxiety. Psilocybin-assisted psychotherapy for major depressive disorder, treatment-resistant depression, and anxiety disorders has been the subject of clinical research and case studies.(15)

Several clinical trials and case studies have explored the use of psilocybin-assisted psychotherapy for depression and anxiety. These studies have shown promising results, with significant reductions in depressive and anxiety symptoms, often lasting for weeks or months after a single psilocybin session. Notably, a randomized controlled trial by Carhart-Harris et al. (16)demonstrated that psilocybin produced rapid and sustained reductions in depressive symptoms in patients with treatment-resistant depression. In a similar study, Ross et al. research showed that individuals with life-threatening cancer diagnoses who received a single dose of psilocybin along with psychotherapy experienced considerable decreases in anxiety and depression. These results suggest that psilocybin-assisted psychotherapy may represent an exciting new treatment option for people with depression and anxiety disorders. It was found that a single dose of psilocybin, combined with psychotherapy, led to significant reductions in anxiety and depression in patients with life-threatening cancer diagnoses. These findings suggest that psilocybin-assisted psychotherapy may offer a promising alternative to traditional treatments for individuals suffering from depression and anxiety disorders.(17)

2.2 Literature search strategy:

To find pertinent papers on the use of psilocybin for depression and anxiety disorders, we conducted a thorough search of electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. Various words and phrases were combined to conduct the search, including "psilocybin," "depression," "anxiety," "psychotherapy," "treatment," "clinical trial," and "case study."

2.3 Study selection:

The following requirements had to be followed for studies to be considered: (a) they had to be original research papers; (b) they had to be concerned with the use of psilocybin for treating depression or anxiety disorders; (c) they had to report on clinical trials, case studies, or observational studies; and (d) they had to be written in English. Studies that didn't fit these requirements, including reviews, commentaries, or pieces not particularly about psilocybin and anxiety or depression, were disregarded.

2.4 Data extraction and synthesis:
We gathered pertinent data for each qualifying trial, including its design, sample size, population, interventional features (such as dose, duration, and therapeutic context), outcome metrics, and major findings. The information was then compiled to give a summary of the most recent research on the security, effectiveness, and workings of psilocybin-assisted psychotherapy for depression and anxiety. By classifying the studies according to the illness being treated (depression or anxiety), we were able to organise the synthesis and emphasise the key findings.

2.5 Quality assessment:
We evaluated the quality of the included studies using appropriate tools, such as the Cochrane Risk of Bias Tool for randomized controlled trials (18) and the Newcastle-Ottawa Scale for observational studies.(19) This assessment helped us identify potential biases and the overall rigor of the evidence presented in the review.

By following these methods, we aimed to provide a comprehensive and critical overview of the existing literature on psilocybin-assisted psychotherapy for depression and anxiety

2.6 Safety and tolerability of psilocybin administration in clinical settings:
Psilocybin has been established in the context of clinical research to be comparatively safe and well-tolerated when delivered under controlled circumstances and with the proper support. The majority of side effects that have been documented are mild to severe and include brief adjustments to perception, emotion, and cognition. Serious adverse events are uncommon, and there doesn't seem to be much of a chance for long-term unfavourable effects. It is important to keep in mind, nevertheless, that the safety profile of psilocybin may change according on elements including dosage, individual susceptibility, and the environment in which it is delivered.

2.7 Potential mechanisms of action, including neuroplasticity and psychological processes:
Current research indicates that the therapeutic effects of psilocybin may involve both neurobiological and psychological processes, while the precise mechanisms of action underlying these effects are still not fully understood. According to research on the neurobiology of psilocybin, it predominantly affects the serotonin 2A (5-HT2A) receptor, altering brain connections and activity. Increased neuroplasticity as a result might lead to long-lasting adjustments in mood, cognition, and behaviour. (20)

Psilocybin-assisted psychotherapy may promote improved introspection, emotional processing, and a feeling of psychological "reset" or reorientation in terms of psychological processes. During their psilocybin sessions, patients frequently describe intense mystical or spiritual experiences that have been linked to long-lasting benefits in wellbeing and symptom relief. Additionally, the therapeutic context—which includes planning, a welcoming atmosphere during the psilocybin session, and follow-up integration work—plays a crucial role in determining the overall therapeutic result. (21)

In summary, psilocybin-assisted psychotherapy has shown promise in the treatment of anxiety and depression. Psilocybin is an exciting area for further study and clinical application due to its safety and tolerability in clinical settings and probable mechanisms of action. To better understand the ideal dose, therapeutic contexts, and patient demographics that may benefit most from this unique therapy method, additional research is required.

3. LSD for Anxiety and Mood Disorders:

3.1 Overview of LSD and its history in research:
The powerful hallucinogen lysergic acid diethylamide (LSD) is derived from the ergot fungus. Swiss chemist Albert Hofmann created it for the first time in 1938, and it wasn't until 1943 that its psychedelic characteristics were identified. Significant research on LSD's potential therapeutic uses, particularly for the management of mood and anxiety disorders, was conducted in the 1950s and 1960s. As with psilocybin, LSD's association with the counterculture movement and subsequent designation as a Schedule I drug led to a significant halt in research. LSD research has recently attracted considerable attention, with a focus on its potential advantages for treating a range of mental health issues.(22)

The effectiveness of LSD-assisted psychotherapy for mood disorders, anxiety disorders, and existential distress in patients with life-threatening illnesses is investigated in clinical trials and case studies. LSD-assisted psychotherapy for mood disorders, anxiety disorders, and existential distress in patients with life-threatening illnesses has been the subject of numerous clinical research and case studies. Anxiety connected to life-threatening illnesses was significantly reduced by LSD-assisted psychotherapy, according to a landmark study by Gasser et al. (2014), with long-lasting effects seen up to 12 months following treatment. Similar beneficial results in patients with anxiety and mood disorders, as well as reductions in symptoms, have been found in another research. These results imply that LSD-assisted psychotherapy may provide a beneficial therapeutic strategy for people dealing with mood and anxiety problems.(23)

3.2 Literature search strategy:
To identify relevant studies on the use of LSD for anxiety and mood disorders, we performed a comprehensive search of electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search was conducted using a combination of keywords and phrases, such as "LSD," "lysergic acid diethylamide," "anxiety," "mood disorders," "depression," "psychotherapy," "treatment," "clinical trial," and "case study." Study selection:

3.3 Study selection
We included studies that met the following criteria: (a) original research articles, (b) focused on the use of LSD for anxiety or mood disorders, (c) reported on clinical trials, case studies, or observational studies, and (d) published in English. We excluded studies that did not meet these criteria, such as reviews, commentaries, or articles not specifically related to LSD and anxiety or mood disorders.

3.4 Data extraction and synthesis:
For each eligible study, we extracted relevant information, including the study design, sample size, population, intervention details (e.g., dose, duration, and therapeutic context), outcome measures, and key findings. We then synthesized the data to provide an overview of the current evidence on the safety, efficacy, and mechanisms of action of LSD-assisted psychotherapy for anxiety and mood disorders. We organized the synthesis by categorizing the studies based on the specific disorder being treated (e.g., anxiety, depression) and highlighting the main findings, trends, and potential limitations in the literature.

3.5 Quality assessment:
We evaluated the quality of the included studies using appropriate tools, such as the Cochrane Risk of Bias Tool for randomized controlled trials and the Newcastle-Ottawa Scale(18,19) for observational studies. This assessment helped us identify potential biases and the overall rigor of the evidence presented in the review.

By following these methods, we aimed to provide a comprehensive and critical overview of the existing literature

on LSD-assisted psychotherapy for anxiety and mood disorders. This approach allows us to assess the current state of the research, identify gaps in knowledge, and make recommendations for future studies in the field.

3.6 Safety and tolerability of LSD administration in clinical settings:

When used properly, LSD has been demonstrated to be relatively safe and well-tolerated when delivered under strict supervision. The majority of adverse effects that have been recorded are mild to moderate and include adjustments in perception, emotional disturbances, and cognitive abnormalities. When administered in a therapeutic setting, serious adverse events are uncommon, and the chance of long-term unfavourable effects is low. When assessing safety and tolerability, it is crucial to take into account both individual factors, such as a person's susceptibility to psychological distress or history of psychiatric illness, as well as the specific circumstances surrounding how LSD is administered.

3.7 Potential mechanisms of action, including altered neural connectivity and psychological processes:

Current research indicates that the therapeutic effects of LSD may be mediated by neurobiological and psychological processes, even though the precise mechanisms behind these effects are still not fully known. LSD predominantly affects the serotonin 2A (5-HT2A) receptor in the brain, altering neuronal activity and connection patterns that may be related to symptom relief. Additionally, it has been demonstrated that LSD increases neuroplasticity, which might help it have therapeutic effects that last a long time.(22)

LSD-assisted psychotherapy may, from a psychological standpoint, promote introspection, emotional processing, and psychological transformation. During LSD sessions, patients frequently experience deep insights, emotional breakthroughs, and a sense of greater self-awareness, which may help to permanently reduce mood and anxiety problems. Additionally, the therapeutic context—which includes planning, a supportive atmosphere during the LSD session, and follow-up integration work—plays a crucial role in determining the overall therapeutic result.

In conclusion, LSD-assisted psychotherapy has shown promise in treating existential distress in patients with life-threatening illnesses, as well as anxiety and mood disorders. LSD presents an exciting area for further study and clinical application due to its safety and tolerability in clinical settings and probable mechanisms of action. Additional studies are needed to better understand the optimal dosing, therapeutic contexts, and patient populations that may benefit most from this novel treatment approach.(24,25)

4. Ayahuasca for Depression and substance use Disorder

4.1 Overview of ayahuasca and its history in traditional use and research:

Indigenous cultures have long employed Ayahuasca, a potent plant-based entheogenic beverage, for ceremonial and therapeutic purposes. The Banisteriopsis caapi vine and Psychotria viridis plant, both of which have leaves that contain the hallucinogenic ingredient N,N-dimethyltryptamine (DMT), are generally used to make the drink. In recent years, ayahuasca has drawn interest because to its possible therapeutic value in the treatment of depression and substance use problems. Although it is still in its early stages, ayahuasca research has been steadily expanding.(26)

Ayahuasca's therapeutic potential for major depressive disorder and substance use disorders, such as alcohol and drug addiction, has been studied in clinical trials and observational studies.

The potential therapeutic benefits of ayahuasca for major depressive disorder and substance use disorders have been investigated in a number of clinical trials and observational studies. In patients with treatment-resistant depression, a single dose of ayahuasca led to rapid and long-lasting improvements in depressive symptoms, according to a study by Palhano-Fontes et al. (2019). Ayahuasca may lessen cravings, withdrawal symptoms, and relapse rates for alcohol and drug addiction, according to observational research and early trials in substance use disorders.(27)

4.2 Literature search strategy:

We conducted a comprehensive search of electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant studies on the use of ayahuasca for depression and substance use disorders. The search was performed using a combination of keywords and phrases, such as "ayahuasca," "depression," "substance use disorders," "addiction," "alcohol," "drugs," "treatment," "clinical trial," and "observational study."

4.3 Study selection:

We included studies that met the following criteria: (a) original research articles, (b) focused on the use of ayahuasca for depression or substance use disorders, (c) reported on clinical trials, case studies, or observational studies, and (d) published in English. We excluded studies that did not meet these criteria, such as reviews, commentaries, or articles

4.4 Data extraction and synthesis:

The study design, sample size, population, intervention specifics (such as ayahuasca dosage, preparation, and context), outcome measures, and important findings were all retrieved for each qualifying study. The information was then compiled to give a summary of the most recent research on the efficacy, safety, and mechanism of action of ayahuasca for depression and substance use disorders. By classifying the studies according to the specific illness they were intended to treat (such as depression, alcoholism, or drug addiction), we were able to organise the synthesis and emphasise the key findings, patterns, and potential limitations in the literature.

4.5 Quality assessment:

We evaluated the quality of the included studies using appropriate tools, such as the Cochrane Risk of Bias Tool(18) for randomized controlled trials and the Newcastle-Ottawa Scale (19) for observational studies. This assessment helped us identify potential biases and the overall rigor of the evidence presented in the review.(28) By following these methods, we aimed to provide a comprehensive and critical overview of the existing literature on ayahuasca for depression and substance use disorders. This approach allows us to assess the current state of the research, identify gaps in knowledge, and make recommendations for future studies in the field. Through this systematic review, we can better understand the potential therapeutic benefits of ayahuasca, the safety and tolerability of its administration in clinical settings, and the underlying mechanisms that contribute to its therapeutic effects.

4.6 Safety and tolerability of ayahuasca administration in clinical settings:

When used in controlled environments and under the supervision of skilled practitioners, ayahuasca is typically regarded as safe and well-tolerated. Temporary nausea, vomiting, and diarrhoea are frequent side effects that are thought to be a natural part of the body's "cleansing" process. Temporary alterations in perception, emotions, and cognition may also occur in certain users. Although serious adverse events are uncommon, it is important to take these into account when assessing the safety and tolerability of ayahuasca. These include possible drug interactions, individual susceptibility, and the environment in which it is administered. It's also important to keep in mind that traditional ayahuasca rituals might vary greatly from clinical

settings, and modifications might be required to maintain safety in research and therapeutic environments.(29,30)

4.7 Potential mechanisms of action, including altered neural connectivity and psychological processes:

Though the precise mechanisms underlying ayahuasca's therapeutic effects are still unknown, recent research leads researchers to believe that they may involve both neurobiological and psychological processes. Ayahuasca's active ingredients, such as DMT and harmine, have been proven to support neurogenesis, increase synaptic plasticity, and regulate brain networks on a neurobiological level, which may help explain some of its therapeutic effects.(27)

The ayahuasca experience frequently entails deep introspection, emotional processing, and the confrontation of personal concerns or past traumas, according to psychological research. The supportive environment of the ceremony or therapy session, along with these experiences, may promote psychological healing and personal development. Ayahuasca users frequently report intense spiritual or mystical encounters, which may be connected to long-lasting enhancements in resilience and well-being.

In conclusion, ayahuasca has demonstrated promising results for the treatment of depression and substance use disorders. The safety and tolerability of ayahuasca in controlled settings, along with its potential mechanisms of action, make it an interesting area for future research and clinical Methods for a Review Article on Ayahuasca for Depression and Substance Use Disorders.

5. MDMA for PTSD

5.1 Overview of MDMA and its history in research:

The synthetic psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) is well-known for having entactogenic and empathogenic effects. It was first created in 1912 by Merck, and in the 1970s and 1980s it became widely used as a recreational drug. Some therapists used MDMA to advance the therapeutic process before it was listed as a Schedule I drug. The potential use of MDMA-assisted psychotherapy for different mental health problems, including PTSD, has recently attracted renewed study.(31)

5.2 Literature search strategy:

To identify relevant studies on the use of MDMA for PTSD, we performed a comprehensive search of electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search was conducted using a combination of keywords and phrases, such as "MDMA (3, 4-methylenedioxymethamphetamine)","trauma","addiction", "psychotherapy" "psychotherapy," "treatment," "clinical trial," and "case study."

5.3 Study selection

We included studies that met the following criteria: (a) original research articles, (b) focused on the use of MDMA for post traumatic stress disorder, (c) reported on clinical trials, case studies, or observational studies, and (d) published in English. We excluded studies that did not meet these criteria, such as reviews, commentaries, or articles not specifically related to MDMA and stress reaction and post traumatic stress disorder.

5.4 Data extraction and synthesis:

For each eligible study, we extracted relevant information, including the study design, sample size, population, intervention details (e.g., dose, duration, and therapeutic context), outcome measures, and key findings. We then synthesized the data to provide an overview of the current evidence on the safety, efficacy, and mechanisms of action of MDMA-assisted psychotherapy for post traumatic stress disorder patients. We organized the synthesis by categorizing the studies based on the specific disorder being treated (e.g., acute stress reaction) and highlighting the main findings, trends, and potential limitations in the literature.

5.5 Quality assessment:

We evaluated the quality of the included studies using appropriate tools, such as the Cochrane Risk of Bias Tool for randomized controlled trials (18)and the Newcastle-Ottawa Scale for observational studies. (19)This assessment helped us identify potential biases and the overall rigor of the evidence presented in the review.

By following these methods, we aimed to provide a comprehensive and critical overview of the existing literature on MDMA-assisted psychotherapy for psychiatric disorders. This approach allows us to assess the current state of the research, identify gaps in knowledge, and make recommendations for future studies in the field.

5.6 Safety and tolerability of MDMA administration in clinical settings

Numerous clinical trials have been conducted to investigate the efficacy of MDMA-assisted psychotherapy for PTSD. Many of these studies have reported significant improvements in PTSD symptoms, with some patients experiencing lasting reductions in symptoms even after a few sessions. For example, a Phase 2 clinical trial conducted by Mithoefer et al. (2018) found that 54% of participants receiving MDMA-assisted psychotherapy no longer met the criteria for PTSD at a 12-month follow-up.(32)

When administered in controlled settings and under the guidance of trained therapists, MDMA is considered safe and well-tolerated. Common side effects include increased heart rate, blood pressure, and body temperature, as well as feelings of anxiety or agitation. These side effects are usually transient and manageable within the therapeutic setting. It is essential to screen potential participants for medical contraindications and provide proper support throughout the therapy process to minimize risks.(33)

5.7 Potential mechanisms of action, including enhanced fear extinction and emotional processing:

We still don't fully understand the precise processes underlying the benefits of MDMA-assisted psychotherapy for PTSD. The effects may, however, be connected to MDMA's capacity to improve emotional processing and fear extinction, according to recent studies. Neurotransmitters like serotonin, dopamine, and norepinephrine are released more readily when MDMA is consumed, and this can improve feelings of empathy, emotional openness, and connection. These outcomes may assist patients in better confronting and processing traumatic memories during therapy sessions, resulting in long-lasting reductions in PTSD symptoms.(27,32)

In conclusion, the use of MDMA in conjunction with psychotherapy has shown promise in the treatment of PTSD. Future research and clinical application in MDMA are highly intriguing due to the drug's safety and tolerance in clinical settings as well as its conceivable modes of action. To better understand the ideal dose, therapeutic contexts, and patient demographics that would benefit most from this unique therapy method, more research is required.

Conclusion:

This review highlights the growing body of evidence suggesting psychedelic substances can be used to treat a range of mental health issues. Even if the present research indicates favourable findings, larger, randomised controlled trials are necessary to demonstrate the safety and efficacy of psychedelic-assisted psychotherapy in a variety of populations. In order to optimise the benefits of these treatments, additional research is also required to clarify the mechanisms of action and identify the best therapy settings,

dose regimens, and integration strategies.

In order to ultimately enhance patient outcomes and widen the range of accessible therapies, more investigation into the potential of psychedelic-assisted psychotherapy to address unmet needs in mental health care is required. Concerns about the ethical, legal, and social repercussions of employing psychedelic substances in conventional psychiatry must be addressed as the discipline matures. By building on the existing studies, the scientific community may increase understanding of the potential benefits and risks of psychedelic-assisted psychotherapy, opening the door for more effective and innovative mental health interventions.

Financial support and sponsorship: Nil

There are no conflicts of interest.

REFERENCES

1. Belouin SJ, Henningfield JE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology. 2018 Nov;142:7–19.
2. Ross S. Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies. Psychiatr Clin North Am. 2012 Jun;35(2):357–74.
3. Malleson N. Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom. Br J Psychiatry. 1971 Feb;118(543):229–30.
4. Malleson N. Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom. Br J Psychiatry. 1971 Feb;118(543):229–30.
5. Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006 Jun 27;66(12):1920–2.
6. Controlled Substance Schedules [Internet]. [cited 2023 May 4]. Available from: https://www.deadiversion.usdoj.gov/schedules/
7. Sessa B. Shaping the renaissance of psychedelic research. The Lancet. 2012 Jul;380(9838):200–1.
8. Timmermann C, Bauer PR, Gosseries O, Vanhaudenhuyse A, Vollenweider F, Laureys S, et al. A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends Cogn Sci. 2023 Feb 1;27(2):139–59.
9. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250–8.
10. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013 Aug;14(8):577–85.
11. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxf). 2008 Aug;22(6):603–20.
12. Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. Can Med Assoc J. 2015 Oct 6;187(14):1054–9.
13. Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci. 2017 Nov;38(11):992–1005.
14. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects | Translational Psychiatry [Internet]. [cited 2023 May 4]. Available from: https://www.nature.com/articles/tp201754
15. https://www.howstuffworks.com/about-shanna-freeman.htm, https://www.howstuffworks.com/about-nathan-chandler.htm. How Magic Mushrooms Work [Internet]. HowStuffWorks. 2009 [cited 2023 May 4]. Available from: https://science.howstuffworks.com/magic-mushroom.htm
16. Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619–27.
17. Ross S. Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies. Psychiatr Clin North Am. 2012 Jun;35(2):357–74.
18. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343(oct18 2):d5928–d5928.
19. Ottawa Hospital Research Institute [Internet]. [cited 2023 May 4]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
20. Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020 Oct;73(10):679–86.
21. Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR. Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus [Internet]. 2022 Feb 5 [cited 2023 May 4]; Available from: https://www.cureus.com/articles/85829-analysis-of-psilocybin-assisted-therapy-in-medicine-a-narrative-review
22. Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017 Oct;42(11):2114–27.
23. Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology (Berl). 2010;208(2):179–89.
24. Marona-Lewicka D, Nichols DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav. 2007 Oct;87(4):453–61.
25. Mueller F, Lenz C, Dolder PC, Harder S, Schmid Y, Lang UE, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017 Apr 4;7(4):e1084.
26. Frecska E, Bokor P, Winkelman M. The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. Front Pharmacol [Internet]. 2016 [cited 2023 May 4];7. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2016.00035
27. Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JAS, Hallak JEC, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PloS One. 2015;10(2):e0118143.
28. Garcia-Romeu A, Kersgaard B, Addy PH. Clinical Applications of Hallucinogens: A Review. Exp Clin Psychopharmacol. 2016 Aug;24(4):229–68.
29. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther. 2009 Nov;124(2):195–206.
30. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004 May;102(2):111–29.
31. Sessa B, Higbed L, Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front Psychiatry [Internet]. 2019 [cited 2023 May 4];10. Available from: https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00138
32. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxf). 2011 Apr;25(4):439–52.
33. 3-Methoxy-4 5-methylenedioxy Amphetamine, a New Psychotomimetic Agent | Nature [Internet]. [cited 2023 May 4]. Available from: https://www.nature.com/articles/2011120a0